In conclusion, class IIa HDACi—firstly—reduce tumor growth of HNSCC with high HDAC4 expression and—secondly—act synergistically in combination with proteasome inhibitors in platinum-resistant HNSCC. Here, HDAC4 is linked to neoplasm.